Teva Pharmaceutical Industries Ltd (NYSE: TEVJF)

Teva Pharmaceutical Industries Ltd is a biopharmaceutical company that combines a strong generics business with innovative medicines biosimilars and over the counter products. The firm develops manufactures and sells a wide range of pharmaceuticals including generic prescription drugs biosimilar biologics and patented treatments across neuroscience immunology respiratory and oncology therapeutic areas. Headquartered in Israel Teva maintains a significant presence in the United States Europe and many other markets worldwide and operates through a global network of approximately 34000 employees across 57 countries. The company was incorporated in Israel on February 13 1944 and traces its origins to enterprises established as early as 1901. Today Teva serves patients and healthcare providers by offering affordable treatment options and innovative therapies that address unmet medical needs.

Teva generates revenue primarily through the sale of generic medicines biosimilar products innovative medicines over the counter items and related services. Its generic portfolio includes oral solids injectables inhalants liquids transdermal patches and creams that are marketed to retail drug chains mail order distributors wholesalers and pharmacies. The biosimilar business offers alternatives to reference biologics such as rituximab trastuzumab and other monoclonal antibodies and is sold to hospitals clinics and specialty care providers. Innovative medicines such as AUSTEDO AJOVY UZEDY and COPAXONE generate revenue through prescriptions for neurological respiratory and oncological indications and are distributed via similar channels. Over the counter products like SUDOCREM and regional brands are sold through retail outlets and pharmacy chains. In addition the company derives income from the sale of active pharmaceutical ingredients to third parties contract manufacturing arrangements and an out licensing platform through its affiliate Medis which offers a portfolio of products to other pharmaceutical firms.

Teva holds a leading position in the global generics market often ranking among the top three suppliers in numerous countries including the United States and several European nations. Its competitive advantages stem from a broad product portfolio integrated research and development capabilities and a worldwide manufacturing and commercial footprint that enables rapid response to market demands. In the biosimilar arena Teva competes with established players such as Sandoz Amgen and Pfizer while leveraging its experience in complex biologics and strategic partnerships to expand its pipeline. Within innovative medicines the company faces competition from both large pharmaceutical firms and generic entrants but maintains differentiation through patented therapies patient support programs and a focus on high unmet need areas such as movement disorders and migraine. Overall Teva’s scale diversified therapeutic focus and commitment to pipeline optimization provide a solid foundation for sustained market relevance.

The company’s customer base consists of retail pharmacies hospital pharmacies wholesalers managed care organizations and government health programs. In the United States major customers include large drug store chains mail order distributors and wholesale drug distributors. In Europe and international markets Teva serves national pharmacy chains hospital groups and public health agencies. Its over the counter products reach consumers through retail outlets and grocery stores while its biosimilar and innovative medicines are used by physicians treating patients in outpatient clinics inpatient facilities and specialty treatment centers. The diversified customer mix helps mitigate reliance on any single channel and supports stable demand across its product lines.